Literature DB >> 1379014

Neurotoxic amphetamine analogues: effects in monkeys and implications for humans.

G A Ricaurte1, U D McCann.   

Abstract

A wealth of evidence has accrued over the last 20 years indicating that certain amphetamine analogues have the potential to damage central monoaminergic neurons. For example, amphetamine has been shown to be toxic to dopamine neurons, MDMA to serotonin neurons, and methamphetamine to both (Table 1). In rodents, the toxic effects of amphetamines appear to be limited to axon terminals, and regenerative sprouting tends to be the rule. By contrast, in primates, nerve cell bodies appear to be affected, and the deleterious effects of amphetamine derivatives tend to be longer lasting, and possibly permanent (Fig. 2). Although findings in animals are compelling, observations in humans are less clear. In particular, it remains to be determined whether amphetamine analogues damage central monoaminergic neurons in humans and, if they do, whether functional consequences ensue. Also, the mechanism by which amphetamines damage monoaminergic neurons remains to be defined. Further insight into these basic and clinical aspects of amphetamine neurotoxicity should enhance our understanding of central monoaminergic systems in normal brain function, and their role in the pathophysiology of neuropsychiatric disorders.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1379014     DOI: 10.1111/j.1749-6632.1992.tb24586.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  29 in total

Review 1.  Neuroimaging in drug abuse.

Authors:  Kimberly P Lindsey; S John Gatley; Nora D Volkow
Journal:  Curr Psychiatry Rep       Date:  2003-10       Impact factor: 5.285

2.  Neurotoxicity of methamphetamine and methylenedioxymethamphetamine.

Authors:  L S Seiden; R Lew; J E Malberg
Journal:  Neurotox Res       Date:  2001-01       Impact factor: 3.911

3.  The differential effects of ecstasy/polydrug use on executive components: shifting, inhibition, updating and access to semantic memory.

Authors:  Catharine Montgomery; John E Fisk; Russell Newcombe; Phillip N Murphy
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

4.  Equivalent effects of acute tryptophan depletion on REM sleep in ecstasy users and controls.

Authors:  Robin L Carhart-Harris; David J Nutt; Marcus R Munafo; David M Christmas; Sue J Wilson
Journal:  Psychopharmacology (Berl)       Date:  2009-07-08       Impact factor: 4.530

Review 5.  Fetal effects of psychoactive drugs.

Authors:  Amy L Salisbury; Kathryn L Ponder; James F Padbury; Barry M Lester
Journal:  Clin Perinatol       Date:  2009-09       Impact factor: 3.430

Review 6.  Neurochemistry of drug action: insights from proton magnetic resonance spectroscopic imaging and their relevance to addiction.

Authors:  Stephanie C Licata; Perry F Renshaw
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

Review 7.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

Review 8.  Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function.

Authors:  M Isabel Colado; Esther O'Shea; A Richard Green
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

9.  Binge-like acquisition of α-pyrrolidinopentiophenone (α-PVP) self-administration in female rats.

Authors:  Mehrak Javadi-Paydar; Eric L Harvey; Yanabel Grant; Sophia A Vandewater; Kevin M Creehan; Jacques D Nguyen; Tobin J Dickerson; Michael A Taffe
Journal:  Psychopharmacology (Berl)       Date:  2018-06-16       Impact factor: 4.530

10.  Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity.

Authors:  S Przedborski; V Jackson-Lewis; R Yokoyama; T Shibata; V L Dawson; T M Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.